文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

恶性疟原虫血症不降低HIV感染者mRNA新冠加强针的中和抗体应答

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究评估了无症状HIV感染成人在接种单价mRNA-1273或二价mRNA-1273.222加强针后,合并或未合并PCR确诊恶性疟原虫血症者的中和抗体应答。

要点

  • ID50=1000与96%预防COVID-19效力相关,本研究中两组滴度均远超该阈值。
  • 无症状恶性疟原虫血症不降低HIV感染者mRNA新冠加强针的中和抗体应答。

核心结论

  • COVID-19 mRNA疫苗抗体应答不受合并无症状疟原虫血症影响。

研究设计与样本

  • 评估无症状HIV感染成人接种单价mRNA-1273或二价mRNA-1273.222加强针后的中和抗体应答,比较PCR确诊合并与未合并恶性疟原虫血症者。

关键数值与推荐

  • 既往研究中ID50中和抗体滴度1000与96%预防COVID-19效力相关。

临床怎么用

  • HIV感染者合并无症状恶性疟原虫血症时,仍可按计划接种mRNA新冠加强针。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

mRNA vaccines have emerged as powerful tools for the prevention of infectious diseases, but subclinical malaria may reduce vaccine immunogenicity. We evaluated neutralizing antibody responses in asymptomatic HIV-infected adults with and without polymerase chain reaction-confirmed Plasmodium falciparum who received either monovalent mRNA-1273 or bivalent mRNA-1273.222 (WA-1 and BA.4/5) booster vaccines. In previous studies, a 50% pseudovirus inhibitory dose neutralizing antibody (ID50) titer of 1000 correlated with 96% efficacy in preventing COVID-19. We observed ID50 geometric mean titers >22 000 in both parasitemic and nonparasitemic participants 1 month after boosting. We conclude that COVID-19 mRNA vaccine antibody responses are unimpaired by concurrent asymptomatic parasitemia.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Samandari T, Achola M, Hutter JN, et al. Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults. J Infect Dis. 2025. PMID: 40751436. doi:10.1093/infdis/jiaf398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。